文献速递腹部外周血管MR

肝脾ΔT1及脾ECV在Gd-EOB-DTPA肝脏MRI无创评估临床显著门脉高压中的价值

Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI.
PubMed 文献 · Eur J Radiol · 2021-09-20

该回顾性研究纳入195例慢性肝病患者,基于脾大伴血小板减少、腹水及门体侧支循环将患者分为无CSPH、代偿性CSPH和失代偿性CSPH组,比较肝脾ΔT1及脾ECV在组间的差异。结果显示肝ΔT1在CSPH组显著降低,其鉴别无CSPH与CSPH的AUC为0.79,优于脾ΔT1(AUC=0.69)和脾ECV(AUC=0.63)。结论认为肝脾ΔT1及脾ECV可在常规Gd-EOB-DTPA肝脏MRI上无创判定CSPH。

要点

  • 肝ΔT1鉴别无CSPH与CSPH的AUC为0.79,优于脾ΔT1和脾ECV。
  • 肝ΔT1 cutoff<0.67时鉴别效能最佳。
  • 脾ΔT1 cutoff>0.29、脾ECV cutoff>41.9时AUC分别为0.69和0.63。

诊断标准与关键数值

  • 肝ΔT1鉴别无CSPH与CSPH的cutoff为<0.67,AUC=0.79。
  • 脾ΔT1鉴别无CSPH与CSPH的cutoff为>0.29,AUC=0.69。
  • 脾ECV鉴别无CSPH与CSPH的cutoff为>41.9,AUC=0.63。
  • CSPH分组标准:脾大伴血小板减少、腹水及门体侧支循环中≥1项且无腹水为代偿性CSPH,腹水±其他表现为失代偿性CSPH。

临床应用与阅片要点

  • 在常规Gd-EOB-DTPA肝脏MRI上可测量肝脾ΔT1及脾ECV辅助无创评估CSPH。
  • 肝ΔT1鉴别效能优于脾ΔT1和脾ECV,阅片时可优先关注肝ΔT1。

局限性

  • 回顾性单中心设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To analyze the predictive value of ΔT1 of the liver and spleen as well as the extracellular volume fraction (ECV) of the spleen as noninvasive biomarkers for the determination of clinically significant portal hypertension (CSPH) on routine Gd-EOB-DTPA liver MRI.

METHOD: 195 consecutive patients with known or suspected chronic liver disease from 9/2018 to 7/2019 with Gd-EOB-DTPA liver MRI and abdominal T1 mapping were retrospectively included. Based on the presence of splenomegaly with thrombocytopenia, ascites and portosystemic collaterals, the patients were divided into noCSPH (n = 113), compensated CSPH (cCSPH, ≥1 finding without ascites; n = 55) and decompensated CSPH (dCSPH, ascites ± other findings; n = 27). T1 times were measured in the liver, spleen and abdominal aorta in the unenhanced and contrast-enhanced T1 maps. Native T1 times and ΔT1 of the liver and spleen as well as ECV of the spleen were compared between groups using the Kruskal-Wallis test with Dunn's post hoc test. Furthermore, cutoff values for group differentiation were calculated using ROC analysis with Youden's index.

RESULTS: ΔT1 of the liver was significantly lower in patients with cCSPH and dCSPH (p < 0.001) compared to patients with noCSPH. In the ROC analyses for differentiation between noCSPH and CSPH (cCSPH + dCSPH), a cutoff of < 0.67 for ΔT1 of the liver (AUC = 0.79) performed better than ΔT1 (AUC = 0.69) and ECV (AUC = 0.63) of the spleen with cutoffs of > 0.29 and > 41.9, respectively.

CONCLUSION: ΔT1 of the liver and spleen in addition to ECV of the spleen allow for determination of CSPH on routine Gd-EOB-DTPA liver MRI.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Catucci D, Obmann VC, Berzigotti A, et al. Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. Eur J Radiol. 2021. PMID: 34571458. doi:10.1016/j.ejrad.2021.109958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。